Navigation Links
Alexza Pharmaceuticals Reports 2010 Third Quarter Financial Results and Provides Business Update
Date:11/9/2010

schizophrenia or bipolar disorder patients.
  • Alexza reacquired the U.S. and Canadian rights for AZ-004 from Biovail Laboratories International SRL (BLS), a wholly-owned subsidiary of Valeant Pharmaceuticals International, Inc.  All AZ-004 rights will revert to Alexza, effective January 16, 2011.

  • "Our top priority is planning for our meeting with the FDA to discuss the CRL, with the goal of establishing a path to obtaining approval for AZ-004.  We expect to meet with the FDA before the end of this year," said Thomas B. King, President and CEO of Alexza.  "Based on the results of the comprehensive clinical development program to date, we continue to believe in the potential for AZ-004 to provide a safe, rapid, and effective treatment option for the approximately 8.1 million patients with schizophrenia or bipolar disorder.  We believe there is a significant market opportunity for this novel therapeutic, and are seeking to partner AZ-004 on a worldwide basis."

    Alexza Financial Results - Periods Ended September 30, 2010 and 2009

    Alexza recorded $744,000 of revenues in the three and nine months ended September 30, 2010, and $9.5 million in the nine months ended September 30, 2009.  The Company recorded no revenues during the three months ended September 30, 2009.  In September 2010, the Company began to recognize revenues related to payments received from Cypress as part of the license agreement signed in August 2010.  In January 2009, Alexza and Endo Pharmaceuticals mutually agreed to terminate their development agreement related to AZ-003 (Staccato fentanyl), at which time Alexza had fulfilled its obligations under the development agreement and recognized the remaining $9.5 million of deferred revenues into revenues.  The Company expects to recognize $40 million of revenues in the fourth quarter of 2010 as a result of the termination of the license and supply agreements between BLS and Alexz
    '/>"/>

    SOURCE Alexza Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
    2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
    3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
    4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
    5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
    6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
    7. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
    8. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
    9. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
    10. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
    11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/3/2015)... DUBLIN , June 02, 2015 ... the addition of the "The Future of ... As they are in a desperate need ... and low cost, drug companies have been increasingly ... enhance their productivity while constantly streamlining their internal ...
    (Date:6/3/2015)... 3, 2015  Varian Medical Systems (NYSE: VAR ), world ... cancer, is expanding in the Middle East ... Saudi Arabia . Varian Medical Systems Arabia, the ... was officially launched today at a ceremony attended by local ... "This move represents the next step in our commitment ...
    (Date:6/3/2015)... June 02, 2015 Research and Markets ... the "2015 Strategies in the US Tumor ... Highlights of the Report Include ... tumor marker testing market. , Major issues ... as key economic, regulatory, demographic, social and technological ...
    Breaking Medicine Technology:The Future of Pharmaceutical Outsourcing: 2015 Report 2Varian Establishes Local Entity in Saudi Arabia to Support Expansion in Middle East 2United States Strategies in the Tumor Marker Testing Market 2015 2
    ... May 5, 2011 Novartis Pharmaceuticals Corporation ("Novartis") announced ... approved Afinitor® (everolimus) tablets for the treatment of progressive ... unresectable, locally advanced or metastatic disease(4). This marks the ... in the US in nearly 30 years(5). ...
    ... FRANCISCO, May 5, 2011 Cardiac Network, Inc. (Other OTC: ... a 1-for-750 reverse stock split (the "Reverse Stock Split"). The ... business and trading on May 6, 2011 (the "Effective Date"). ... changed from "CNWI" to "CNWID" for approximately 20 business days, ...
    Cached Medicine Technology:Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET 2Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET 3Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET 4Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET 5Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET 6Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET 7Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET 8Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET 9Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET 10Cardiac Network Announces Reverse Stock Split 2
    (Date:6/3/2015)... A group of nine authors involved with ... Inspire Award at DIA’s upcoming Annual Meeting. DIA’s Global ... their leadership, level of excellence, and commitment to service ... of the Author(s) of the Year Award, which acknowledges ... made a significant impact in advancing medical product development, ...
    (Date:6/3/2015)... 03, 2015 Z-Medica®, LLC, a leading ... June has been designated as National Safety Month by ... AZ. Police Department for its commitment to public safety. ... their Individual First Aid Kits (IFAK) over 100 times ... shootings, stabbings or traffic accidents. Each kit is equipped ...
    (Date:6/3/2015)... June 03, 2015 Researchers at the ... for mesothelioma and say the tried-and-true marker mesothelin is ... an article on the research. Click here to ... National Center for Asbestos Related Diseases say, even though ... it is still preferable to fibulin-3 for identifying mesothelioma. ...
    (Date:6/3/2015)... According to an article published on May14th by ... pills which actually contained the potent addictive drug fentanyl. ... even sported the “A/215” imprint common on real oxycodone ... oxycodone to be exceptionally critical of their prescriptions—especially those ... on the street. Fentanyl is an opiate-based narcotic and ...
    (Date:6/3/2015)... Atlanta, GA (PRWEB) June 03, 2015 ... A in Duluth, GA will celebrate its grand opening ... 2015. , The first prosthetic center of its kind ... and their family unmatched care and outcomes through use ... Keith Watson, CPO & CEO of Fourroux Prosthetics, states, ...
    Breaking Medicine News(10 mins):Health News:Authors Representing TransCelerate BioPharma Inc. to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 2Health News:Authors Representing TransCelerate BioPharma Inc. to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 3Health News:Authors Representing TransCelerate BioPharma Inc. to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 4Health News:Z-Medica Commends Tucson Police Department for Trauma Kit Utilization 2Health News:Analysis Reveals Gold Standard Mesothelioma Biomarker Still the Best, According to Surviving Mesothelioma 2Health News:Fake Oxycodone Pills of Fentanyl Discovered in Tennessee by Police 2Health News:Fake Oxycodone Pills of Fentanyl Discovered in Tennessee by Police 3Health News:Fourroux Prosthetics Atlanta to Have Grand Opening Gala & Ribbon Cutting Ceremony 2
    ... Eric Artz and team from the Institute of Tropical Medicine ... AIDS, in which they have said that the HIV virus ... is now more sensitive to anti-retroviral drugs compared to the ... the HIV samples collected in between 1986-89 with the samples ...
    ... disease may not require blood transfusion as a ... form of severe thalassaemia in many Asian// countries—can ... a research letter published online in the September ... the finding has important implications for supplies of ...
    ... single protein has helped bald mice to get fur on ... balding men., ,Catherine C. Thompson and colleagues at Johns ... known as Hairless, which encodes a protein that is essential ... with mutations in the Hairless gene, hair growth is initially ...
    ... ban the Environmental Protection Agency (EPA) from using human ... Lawmakers on Capitol Hill will soon decide whether to ... use of studies that expose participants to pesticides. In ... have their pesticides approved by the agency for marketing. ...
    ... some people vulnerable to suffer from the dreaded disease ... diagnose the risk//. ,According to the most complete ... the researchers from Vanderbilt University in Nashville, Tennessee at ... in San Diego, a cluster of genes on chromosome ...
    ... a limit to how tiny gadgets, devices and machines ... from an experiment performed by a University of Arizona// ... and assistant professor of physics Alexander D. Cronin. ... can come to a surface before the atoms' wavelengths ...
    Cached Medicine News:Health News:US Senate Votes against Testing of Pesticide on Humans 2Health News:Nanotechnologists Specify Limitation For Devising Small Machines 2
    ... product solutions were developed to assist in ... To maximize use of existing capital equipment, ... the productivity of their employees, organizations are ... their valuable assets and ensure those assets ...
    ... Mobile Location-ID™ offers a for asset tracking electronically. ... to all the assets that will be tracked. ... equipped with a reader, antenna, and a portable ... small as 10 inches x 6 inches. One ...
    Radianse indoor positioning supports healthcare asset management with a way to locate medical equipment, devices and other portable assets....
    ... provides hospitals with a suite ... all their supplies, drugs, assets, ... remove all manual compliance from ... accurately. iRIS, or Intelligent Radio-Frequency ...
    Medicine Products: